{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:56:56Z","timestamp":1765976216247,"version":"3.48.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"DOI":"10.7759\/cureus.99450","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:46:43Z","timestamp":1765975603000},"source":"Crossref","is-referenced-by-count":0,"title":["Improving Access to Outpatient Antibiotic Therapy: Addition of Dalbavancin to a County Hospital Formulary for Complicated Staphylococcus aureus Infections"],"prefix":"10.7759","author":[{"given":"Saira","family":"Butt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Tieman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B","family":"Kressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bree","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.01.003","article-title":"Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it","volume":"26","author":"Eichenberger EM","year":"2020","unstructured":"Eichenberger EM, Fowler VG Jr, Holland TL. Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it. Clin Microbiol Infect. 2020, 26:536-8. 10.1016\/j.cmi.2020.01.003","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1756","article-title":"The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database","volume":"165","author":"Noskin GA","year":"2005","unstructured":"Noskin GA, Rubin RJ, Schentag JJ, et al.. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med. 2005, 165:1756-61. 10.1001\/archinte.165.15.1756","journal-title":"Arch Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen K","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, et al.. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019, 380:415-24. 10.1056\/NEJMoa1808312","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li HK","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, et al.. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019, 380:425-36. 10.1056\/NEJMoa1710926","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3138","article-title":"Outpatient parenteral antimicrobial therapy in vulnerable populations - people who inject drugs and the homeless","volume":"14","author":"Beieler A","year":"2019","unstructured":"Beieler A, Magaret A, Zhou Y, Schleyer A, Wald A, Dhanireddy S. Outpatient parenteral antimicrobial therapy in vulnerable populations - people who inject drugs and the homeless. J Hosp Med. 2019, 14:105-9. 10.12788\/jhm.3138","journal-title":"J Hosp Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.inhs.2025.100001","article-title":"Transforming disease management: the clinical benefits of long-acting injectable drug delivery systems","volume":"1","author":"Rathore G","year":"2025","unstructured":"Rathore G, Singh RP. Transforming disease management: the clinical benefits of long-acting injectable drug delivery systems. Intelligent Hospital. 2025, 1:100001. 10.1016\/j.inhs.2025.100001","journal-title":"Intelligent Hospital"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02385-22","article-title":"Evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital","volume":"11","author":"Lueking R","year":"2023","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. Evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital. Microbiol Spectr. 2023, 11:e0238522. 10.1128\/spectrum.02385-22","journal-title":"Microbiol Spectr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic S","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al.. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018, 67:795-8. 10.1093\/cid\/ciy279","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo U","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al.. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019, 6:ofy331. 10.1093\/ofid\/ofy331","journal-title":"Open Forum Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn C","year":"2019","unstructured":"Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019, 6:ofz028. 10.1093\/ofid\/ofz028","journal-title":"Open Forum Infect Dis"},{"key":"ref11","unstructured":"Indiana Medicare plans in 2026. (2025). Accessed. July 19, 2025: https:\/\/www.healthline.com\/health\/medicare\/medicare-plans-in-indiana."},{"key":"ref12","unstructured":"Dalbavancin compared to standard of care in patients that require long-term intravenous antimicrobial therapy that cannot receive outpatient intravenous antimicrobial therapy. (2023). Accessed. August 8, 2025: https:\/\/www.slideshare.net\/slideshow\/dalbavancin-at-iuh-blankemeier_caroline-1-pptx\/281796046."},{"key":"ref13","article-title":"Core competencies and functions of implementation support practitioners","author":"Khan S","year":"2024","unstructured":"Khan S, Manalili K, Moore JE. Core competencies and functions of implementation support practitioners. The Center for Implementation. 2024,","journal-title":"The Center for Implementation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalbavancin","volume":"61","author":"Molina KC","year":"2022","unstructured":"Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical pharmacokinetics and pharmacodynamics of dalbavancin. Clin Pharmacokinet. 2022, 61:363-74. 10.1007\/s40262-021-01088-w","journal-title":"Clin Pharmacokinet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","author":"Turner NA","year":"2025","unstructured":"Turner NA, Hamasaki T, Doernberg SB, et al.. Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA. 2025, e2512543. 10.1001\/jama.2025.12543","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6506a1","article-title":"Core elements of outpatient antibiotic stewardship","volume":"65","author":"Sanchez GV","year":"2016","unstructured":"Sanchez GV, Fleming-Dutra KE, Roberts RM, Hicks LA. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep. 2016, 65:1-12. 10.15585\/mmwr.rr6506a1","journal-title":"MMWR Recomm Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417213-improving-access-to-outpatient-antibiotic-therapy-addition-of-dalbavancin-to-a-county-hospital-formulary-for-complicated-staphylococcus-aureus-infections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:46:50Z","timestamp":1765975610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417213-improving-access-to-outpatient-antibiotic-therapy-addition-of-dalbavancin-to-a-county-hospital-formulary-for-complicated-staphylococcus-aureus-infections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.99450","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}